Hermansen JU, Athanasiadis P, Yin Y, Rise AF, Arribas AJ, Cascione L, Russnes HG, Helland Å, Mato AR, Bertoni F, Tjønnfjord GE, Aittokallio T, Skånland SS (2025)
Proteasome inhibition overcomes resistance to targeted therapies in B-cell malignancy models and in an index patient
Cell Death Dis, 16 (1), 555
DOI 10.1038/s41419-025-07884-7, PubMed 40701968

Chen IM, Johansen JS, Theile S, Silverman LM, Pelz KR, Madsen K, Dajani O, Lim KZM, Lorentzen T, Gaafer O, Koniaris LG, Ferreira AC, Neelon B, Guttridge DC, Ostrowski MC, Zimmers TA, Nielsen D (2025)
Erratum: Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Survival and Cachexia
J Clin Oncol, JCO2501631 (in press)
DOI 10.1200/JCO-25-01631, PubMed 40700669

Lunde P, Bye A, Grimsmo J, Pripp AH, Ritschel V, Jarstad E, Nilsson BB (2025)
Authors' Reply: The Transtheoretical Model: Is It Still the Best We Have?
J Med Internet Res, 27, e79131
DOI 10.2196/79131, PubMed 40698751